These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26814890)

  • 1. Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
    Sang F; Ding Y; Wang J; Sun B; Sun J; Geng Y; Zhang Z; Ding K; Wu LL; Liu JW; Bai C; Yang G; Zhang Q; Li LY; Chen Y
    J Med Chem; 2016 Feb; 59(3):1184-96. PubMed ID: 26814890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells.
    Takeuchi M; Ashihara E; Yamazaki Y; Kimura S; Nakagawa Y; Tanaka R; Yao H; Nagao R; Hayashi Y; Hirai H; Maekawa T
    Cancer Sci; 2011 Mar; 102(3):591-6. PubMed ID: 21166958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators.
    Schoepf AM; Salcher S; Obexer P; Gust R
    Eur J Med Chem; 2020 Jan; 185():111748. PubMed ID: 31648125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
    Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
    Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
    Liu Z; Zheng W; Liu Y; Zhou B; Zhang Y; Wang F
    Exp Cell Res; 2021 Aug; 405(2):112708. PubMed ID: 34157313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.